Are we finally looking at a real functional cure for Type 1 diabetes?

0:00 Good day, type 1 diabetic warriors. Today we have a clearer picture of the Vert.Ex VX880 trials, specifically the 11 of 12 success rate. Now, today I want to get away from all the hype and I want to look at this strategically the way an investor would. Do we have enough momentum to actually push this to a phase 3 clinical trial and hopefully get to the finish line? We've got all the numbers. We're going to review them for you right here, right now. >> Vert.Ex VX880 update. 11 of 12 patients off insulin. Every January, the biotech world gathers for the JP Morgan Healthcare Conference. Think of it as the Super Bowl of biotech. It's where

0:45 companies drop their biggest updates to impress investors for the year ahead. And this year, the conversation around type 1 diabetes has shifted. For the last 2 years, we've heard about one patient here, one patient there. Miraculous but singular. But investors don't bet billions on miracles. They bet on consistency. Let's break down exactly what forward momentum looks like in the data. We are looking at the full dose cohort. Out of 12 patients who received the full target dose of cells, 11 achieved insulin independence. That is a 92% success rate. In the world of clinical trials, that isn't just good, that is statistically massive. But look closer at the HBA1C levels. We aren't just seeing patients off insulin. We are

1:31 seeing their A1C drop to below 7.0% and in many cases into the normal range. And the most critical data point for the FDA, zero severe hypoglycemic events occurred after the treatment took hold. This is the difference between a science experiment and a viable product. It's no longer about does it work. It's about does it work every time. That's great, but they're still on imunosuppressants. You are absolutely right. The 11 patients who are cured of insulin injections are not cured of pills. They are trading one burden for another to keep those cells alive. But here is why this matters for us. The warriors who aren't in this trial. You cannot build a roof until you pour the foundation. VX880 proves the cells work. That is the

2:19 foundation. Once that is proven reliable, which this 11 of 12 data does, Vert.Ex can move to the next product. Once that foundation is set, the mission shifts to protection. We know the first attempt at an encapsulation device VX264 was discontinued because it simply didn't allow the cells to survive and produce enough insulin. But that doesn't kill the dream. It refineses the strategy. Vertex is now actively looking for a workaround. Whether that's a completely new device architecture or potentially partnering these proven cells with a different technology to shield them, the 11 of 12 win proves the engine works. Now they just need to build the right car around it. Now we have to address the headlines

3:05 about adverse events. There were reports of deaths in the broader trial scope. I want to be crystal clear. The data indicate these were unrelated to the stem cells themselves. We are talking about surgical complications or pre-existing conditions unrelated to the treatment mechanism. So where does this leave us? The consistency of this data is exactly what the FDA needs to see to approve a pivotal phase 3 trial. This is the final hurdle before commercial approval. The 11 of 12 success rate is essentially the green light that tells investors and us that the finish line is actually visible. So did Vert.Ex techs win the Super Bowl of biotech. If the goal was to prove that a functional cure is reproducible, then yes, we are moving

3:52 from experimental hope to clinical consistency. And for a disease that is defined by its unpredictability, consistency is the most hopeful thing I've heard in a long time. I'll keep tracking the phase 3 announcements as they happen. Until then, keep fighting, warriors. >> Okay, VX880 update. I think that's all very encouraging. I think that um they made a good presentation and this is all about the money chase. You have to you have to have these projects funded. So VX880 and Vertex is a big company with a quite a bit of money. So I'm very confident that they are still leading this horse race. With regard to immunosuppression, I'm also very confident that they are going to find a

4:38 workaround. Whether it's something that they create themselves, whether they rely on cell pouch technology or whether it is taking the cells that they grow and then re-engineering them using crisper technology could be it could be a conglomeration of many things, but I am very confident and I hope you found this to be good news. Hit the like and subscribe button if you haven't already done so. And of course, you can always support this channel by going to our description, hitting the link, and buying us a coffee. For all those of you who have supported us through buying us a coffee, we thank you very much. And we'll have another great video for you here on all things type 1 diabetes in just a few days.